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The E-cadherin-catenin complex provides cell-cell adhesion. In order for a carcinoma to metastasize, cancer cells must let go of
their hold of neighboring cells in the primary tumor. The presence of components of the E-cadherin-catenin complex in 246
rectal adenocarcinomas was examined by immunohistochemistry and compared to their presence in 219 colon carcinomas. The
expression data were correlated to clinical information from the patients’ records. There were statistically signiﬁcant diﬀerences
in protein expression between the rectal and the colon carcinomas regarding membranous β-catenin, γ-catenin, p120-catenin,
and E-cadherin, as well as nuclear β-catenin. In the rectal carcinomas, there was a signiﬁcant inverse association between the
expression of p120-catenin in cell membranes of the primary tumors and the occurrence of local recurrence, while membranous
protein expression of β-catenin was inversely related to distant metastases.
1.Introduction
The E-cadherin-catenin complex provides cell-cell adhesion.
It is located at the cell membrane of epithelial cells and
consists of a chain of proteins. The outermost element is E-
cadherin, also called uvomorulin, which is a transmembrane
glycoprotein [1]. E-cadherin protrudes outside the cell
membraneandadherestoE-cadherinfromneighboringcells
through calcium-dependent homophilic interaction. The
inner end of the protein chain connects to actin ﬁlaments of
the cytoskeleton in cytosol [2]. Catenins are proteins in the
middle of the chain. They connect actin to E-cadherin [3–
8]. A molecule called Eplin binds α-catenin to actin [9]. α-
cateninisconnectedtoeitherβ-catenin[10,11]orγ-catenin,
also called plakoglobin [3], which in turn are connected to
E-cadherin. Distinct from this, β-catenin [12]a n dγ-catenin
[13] also are translocated to the nucleus and participate in
the Wingless pathway.
In the Wingless (=Wnt) pathway, β-catenin, that is not
bonded,translocatesfromthecytosoltothenucleus.Here,in
a complex with T cell factor (TCF) and Lymphoid enhancer-
binding factor (LEF), β-catenin controls expression of sev-
eral genes, among them Snail1 [14]. Snail1 increases the
expression of the Forkhead box C2 (FOXC2) gene. So do
TGF-beta1, Twist, and Goosecoid. Overexpression of FOXC2
induces epithelial-mesenchymal transition (EMT) [15]. In
EMT, an epithelial cancer cell loses its epithelial character-
istics, among them adherens junctions, and acquires traits of
mesenchymal cells and ﬁbroblasts. This facilitates metastasis.
Snail1 represses the transcription of E-cadherin [16, 17]. The
reduction in E-cadherin induces a positive feedback loop by
its liberation of β-catenin that would otherwise be combined2 Gastroenterology Research and Practice
Table 1: Rectal and colon cancers’ characteristics no. (%).
Rectal Cancers
Gender Males: 150 (61) Females: 96 (39)
Age at operation Lowest: 16 Mean: 66 Highest: 90
Dukes’ stage A: 45 (18) B: 100 (41) C: 69 (28) D: 30 (12)
T stage T1: 8 (3) T2: 46 (19) T3: 187 (76) T4: 5 (2)
N stage N0: 154 (63) N1: 63 (26) N2: 29 (12)
M stage M0: 214 (87) M1: 30 (12)
Tumor diﬀerentiation Poor: 7 (3) Moderate: 235 (96) High: 2 (1)
Colon Cancers
Gender Males: 105 (48) Females: 114 (52)
Age at operation Lowest: 40 Mean: 70 Highest: 93
Dukes’ stage A: 10 (5) B: 105 (48) C: 57 (26) D: 47 (22)
T stage T1: 4 (2) T2: 27 (12) T3: 173 (79) T4: 14 (6)
N stage N0: 137 (63) N1: 65 (30) N2: 15 (7)
M stage M0: 169 (77) M1: 47 (22)
Tumor diﬀerentiation Poor: 23 (11) Moderate: 184 (84) High: 11 (5)
with E-cadherin in the E-cadherin-catenin complex by the
cell membrane [18]. The liberated β-catenin can enter the
Wingless pathway, so causing increased expression of Snail1.
p120-catenin stabilizes E-cadherin by controlling E-
cadherin turnover at the cell membrane. p120 absence dra-
matically accelerates E-cadherin degradation [19, 20]. p120
also contributes to supply the cell surface with E-cadherin
by recruiting kinesin to cadherin-catenin-containing vesicles
[21]. p120 is also supposed to play a role in carcinogenesis
independent of E-cadherin. However, the mechanism is still
not fully understood [22]. p120 can also be translocated to
the nucleus to interact with transcription factor Kaiso [23].
Mild overexpression of Kaiso enhances β-catenin signaling,
whereas higher levels of Kaiso expression inhibit β-catenin
signaling [24].
Adherens junctions are cellular structures found near the
apical surface of polarized epithelial cells. They provide cell-
cell adhesion. The E-cadherin-catenin complex is typically
found in adherens junctions [25, 26], but the E-cadherin-
catenin complex also appears outside adherens junctions
[4, 26, 27].
In order for a carcinoma to metastasize, cancer cells
must detach from neighboring cells in the primary tumor.
This process requires a malfunction of the E-cadherin-
catenin complex. Several studies have demonstrated reduced
expression of E-cadherin [28–35] and catenins [32–34, 36–
43] in a number of carcinomas. All these studies indicate
that E-cadherin/catenin-mediated cell adhesion is crucial in
development and progression of human carcinomas [44],
and E-cadherin acts as an invasion and metastasis suppressor
molecule in cancer [26, 45–47]. p120 loss appears to be an
early event in tumor progression [48].
A simultaneous investigation of the protein expression
of both E-cadherin and all the catenins in the E-cadherin-
catenin complex in only rectal carcinomas has so far never
been performed. Most of the previous studies have included
both rectal and colon carcinomas. Since there are clinical
diﬀerences in prognosis and outcome between patients
operated for rectal and colon carcinomas, as well as reports
about tumor biological diﬀerences between these two tumor
types [49], we aimed in the present study at evaluating
the expression of proteins known to play a pivotal role in
the metastatic process, in rectal adenocarcinomas solely. We
also wanted to explore whether there may be diﬀerences
in expression patterns of these proteins between rectal and
colon adenocarcinomas.
2.MaterialsandMethods
2.1. Patient Materials. Available paraﬃn-embedded tumor
samples from a consecutive series of 274 rectal adenocarci-
nomas removed surgically at Akershus University Hospital
in the years 1992–2000 were scrutinized for inclusion into
the survey. These surgical treatments were all primary opera-
tions. Tumors at a level of 15 centimeters (5.9 inches) or less
from the anal verge (i.e., the outer border of the anus) were
included (246 patients), in accordance with the somewhat
arbitrary range of 15 to 18 centimeters commonly used to
deﬁne the border between rectum and colon. The most
restrictive border was chosen in order to avoid unintentional
inclusion of sigmoid tumors. The clinico-histopathological
characteristics of the patients are shown in Table 1.
Out of 246 patients, 25 experienced a local recurrence
of their rectal cancer. Among those included in the statis-
tical analyses, mean time from primary operation to local
recurrence was 2.4 years. Minimum time was six months,
maximum 6.0 years. For patients with no local recurrence,
mean observation time was 6.7 years (range 4 days–14.5
years). Out of 246 patients, 49 developed distant metastases
from their rectal cancer. Among those included in the
statistical analyses, mean time from primary operation to
distant metastases was 2.3 years. Minimum time was two
months, maximum 12.9 years. For patients without distant
metastases, mean observation time was 7.2 years. Minimum
observation time was four days, maximum 14.4 years.Gastroenterology Research and Practice 3
Table 2: Primary antibodies used for immunohistochemistry.
Antibody Retrieval method Dilution Incubat time Host species Clone Vendor
α-catenin Dako TRS high pH 1:150 30 minutes Mouse, monoclonal 25B1 BD Biosciences Europe∗
β-catenin Tris/EDTA pH 9 1:300 30 minutes Mouse, monoclonal 17C2 Novocastra†
γ-catenin Tris/EDTA 1:25 30 minutes Mouse, monoclonal 11B6 Novocastra†
p120-catenin Dako TRS high pH 1:75 30 minutes Mouse, monoclonal 15D2 Santa Cruz Biotechnology‡
E-cadherin Dako TRS high pH 1:100 30 minutes Mouse, monoclonal NCH-384 Dako∗∗
∗BD Bio Sciences Europe, Norge@Europe.bd.com.
†Novocastra, Newcastle, UK.
‡Santa Cruz Biotechnology, Inc., Europe@scbt.com.
∗∗Dako, N-1086 Oslo, Norway.
This material of rectal carcinomas was compared to a
material examined by Bondi et al. of 219 colon carcinomas
operated on at Akershus University Hospital during the years
1988, 1990, and 1997–2000 [28, 50].
2.2. Immunohistochemistry. Serial sections (3-4 microme-
ters) from formalin ﬁxed, paraﬃn wax embedded archive
tumor tissue were applied to coated slides before immuno-
histochemical staining, where diﬀerent methods were
used.
For β-catenin, sections were dried at 50–60◦C overnight,
deparaﬃnized and rehydrated before antigen retrieval was
performed using microwave technique (20 minutes at
100◦C). Staining was done in Dako Autostainer (Dako
Corporation, Carpinteria, CA).
Sections for α-catenin, p120-catenin, and E-cadherin
were dried overnight at 50–60◦C before pretreatment with
Dako PT link (20 minutes in 98◦C), and staining in Dako
Autostainer (Dako Corporation, Carpinteria, CA), using
Dako’s EnVision Flex-system, with mouse-linker in p120-
catenin and E-cadherin.
For γ-catenin, sections were ﬁxed in incubator 30–40
minutes at 56◦C, and overnight at 37◦C. The immunostain-
ing was performed in Ventana ES Benchmark automated
slide stainer (Ventana Medical Systems, Tucson, AZ), anti-
body diluent (251-018). The details of each antibody used
are shown in Table 2.
The antibodies were visualized for light microscopy with
Envision Plus-System and diaminobenzidine (DAB), and
with Detection Kit Ventana iViewTM DAB, respectively.
Counter-staining was done with Hagen’s haematoxylin for
visualization of tissue structures. Positive control was a
test block with normal colon mucosa and multiple colonic
adenocarcinomas with diverse diﬀerentiation.
The percentage of positive cell membranes was counted
semiquantitatively by applying four deﬁned grades of
immunopositivity. When 60% or more of the cancer cells
were stained, we scored the tumor as grade three. Staining
of 30%–59% of the cells was classiﬁed as grade two. When
5%–29% of the cells were stained, the score was grade one.
Positivity in less than ﬁve percent of cells qualiﬁed for grade
zero. The protein expression was regarded positive regardless
of whether the expression was mainly at the apical portion
of the cell [51, 52]o ri fi ta p p e a r e dt ob er e l a t i v e l ye v e n l y
distributed around the cell membrane.
Scoring of nuclear staining of β-catenin was done in the
same way as for the membranes, except for that the border
between grade zero and grade one was set to zero percent of
the nuclei being stained. The reason for this is that normally,
there should be no staining of nuclear β-catenin at all. Only
clearly nuclear staining was recorded as positive.
We intended to compare our results from rectal cancers
to results from a similar examination of colon cancers pre-
viously performed. Therefore, our method for quantifying
proteins in question had to be the same, with the same cut-
oﬀs between the scored grades. Originally, the choice of four
levels of staining were applied as a compromise between
the wish of detailed measurements and the wish of not
giving the impression of being more accurate than manual
humanjudgmentisinreallife.Oneintentionwiththesystem
was that alterations in protein staining in a cancer should
be larger than alterations naturally occurring in normal
mucosaltissuebeforetheywererecordedaspathological.For
most slides, we were able to check that this intention was
followed,becausealmostallslidescontainednormaladjacent
mucosa in addition to the cancer. The normal mucosa served
as an internal control. In other, earlier, similar investigations,
varying cut-oﬀs have been used, and no uniﬁed, generally
applied standard seems to exist for this. So, in addition to
the above mentioned, the original cut-oﬀs were somewhat
arbitrarily chosen.
At least 100, usually more than 1000 cells, were examined
in each slide. All slides were primarily judged by RAA.
In addition, judgment of slides was done by AB, IRKB,
JB, or SNA, depending on the type of slide in question.
When necessary, consensus was achieved by simultaneous
examination by two examiners in a double microscope.
2.3. Statistics. Statistical analyses were performed by SPSS
version 16.0 running on Windows XP. Binary logistic regres-
sionanalysisandCoxregressionanalysiswereperformed.We
made test plots for proportional hazards for the Cox analyses
and found them satisfactory. An alpha level of statistical
signiﬁcance of P<. 05 was chosen.
In all statistical analyses, we included patient gender,
tumor diﬀerentiation grade, Dukes’ tumor stage, and patient
age at surgery as well as the ﬁve membrane proteins α-
catenin, β-catenin, γ-catenin, p120-catenin, and E-cadherin,
and also nuclear β-catenin, into the same multivariate
analysis.4 Gastroenterology Research and Practice
Figure 1: Representative example of immunopositivity grade 3 for
α-catenin (original magniﬁcation x400).
Figure 2: Representative example of immunopositivity grade 3 for
β-catenin (original magniﬁcation x400).
3. Results
Figures 1, 2, 3, 4,a n d5 show representative examples of
immunostaining.
The immunohistochemical scores for the membrane
proteins as well as nuclear β-catenin in the rectal and the
colon adenocarcinomas are shown in Table 3. There were
signiﬁcant diﬀerences in protein expression between the
rectal and the colon cancers regarding membranous staining
of β-catenin, γ-catenin, p120-catenin and E-cadherin, and
regarding nuclear staining of β-catenin (Table 4). That is,
all examined proteins except α-catenin showed signiﬁcant
diﬀerences.
In the rectal carcinomas, there was a signiﬁcant inverse
relationship between the expression of p120-catenin in cell
membranes of the primary tumors and the occurrence of
local recurrence (Cox analysis, P = .030, HR = 0.492,
95% CI for HR [0.260; 0.932]). There was also a signiﬁcant
inverse relationship between the expression of β-catenin in
cell membranes of the primary tumors of the rectal cancers
and the occurrence of metastases (Cox analysis, P = .003,
HR = 0.579, 95% CI for HR [0.404; 0.829]).
4. Discussion
Results from the present study indicate diﬀerences between
rectal and colon cancers in expression patterns of adhesion
proteins. The present study also demonstrates, for the ﬁrst
time, that reduced protein expression of p120-catenin in cell
membranes of primary rectal carcinomas is associated with
more often local recurrence. Reduced protein expression of
Figure 3: Representative example of immunopositivity grade 3 for
γ-catenin (original magniﬁcation x400).
Figure 4: Representative example of immunopositivity grade 3 for
p120-catenin (original magniﬁcation x400).
Figure 5: Representative example of immunopositivity grade 3 for
E-cadherin (original magniﬁcation x400).
β-catenin in cell membranes of primary rectal carcinomas
more often gave distant metastases.
To our knowledge, no previous study exists on p120-
catenin in a material solely of rectal cancers. Results regard-
ingp120-cateninincolonandcolorectalcancersdiverge.Ina
study exclusively on colon cancers, there was no relationship
between the expression of p120-catenin and metastasis or
survival [28]. Colorectal cancers, that is, a mixture of colon
and rectal cancers, with loss of p120-catenin expression have
b e e nf o u n dt ob em o r el i k e l ym e t a s t a t i ct ol y m p hn o d e s
and distant organs and result in poor survival [53]. An
interpretation of these results and the results of the present
study could be that reduction of p120-catenin expression is
associated with adverse clinical eﬀect only in rectal cancers.
Fernebro et al. found that reduced membranous staining
of β-catenin in rectal cancer correlated signiﬁcantly to
development of metastases, but only in univariate analysisGastroenterology Research and Practice 5
Table 3: Immunohistochemical scores in the rectal and colon adenocarcinomas no. (%).
Protein Immunohistochemical score Total
01 2 3
Rectal Cancers
α-catenin 0 (0) 8 (3) 30 (13) 195 (84) 233 (100)
β-catenin membranous 4 (2) 10 (4) 8 (4) 204 (90) 226 (100)
β-catenin nuclear 12 (5) 130 (55) 47 (20) 46 (20) 235 (100)
γ-catenin 1 (0) 6 (3) 5 (2) 221 (95) 233 (100)
p120-catenin 1 (0) 4 (2) 21 (9) 209 (89) 235 (100)
E-cadherin 0 (0) 1 (0) 4 (2) 220 (98) 225 (100)
Colon Cancers
α-catenin 56 (28) 35 (17) 65 (32) 46 (23) 202 (100)
β-catenin membranous 65 (32) 52 (25) 46 (22) 43 (21) 206 (100)
β-catenin nuclear 126 (78) 34 (21) 2 (1) 0 (0) 162 (100)
γ-catenin 115 (56) 41 (20) 31 (15) 18 (9) 205 (100)
p120-catenin 105 (54) 53 (27) 18 (9) 19 (10) 195 (100)
E-cadherin 90 (44) 59 (29) 30 (14) 26 (13) 205 (100)
Table 4: Diﬀerences in expression of membrane proteins and nuclear β-catenin between rectal and colon adenocarcinomas. Binary logistic
regression.
Protein Highest in P OR 95% CI for OR
β-catenin membranous Rectum .005 11.999 2.121 67.872
γ-catenin Rectum .023 3.141 1.167 8.453
p120-catenin Rectum .002 7.045 2.009 24.706
E-cadherin Rectum 0.004 12.996 2.319 72.824
α-catenin Non-signiﬁcant .348 1.972 0.478 8.137
β-catenin nuclear Rectum .004 83.070 4.155 1660.942
[54]. This is in accordance with our ﬁndings, but we found
this relation to be signiﬁcant in multivariate analysis, where
also possible confounders were included in the statistical
analysis. Protein expression of β-catenin in cell membranes
did not associate with patient prognosis in colon cancers
[28]. A study of colorectal cancers, that is, a mixture of
rectal and colon cancers, showed that loss of membranous
expression of β-catenin was associated with short survival
and death from metastatic colorectal cancer, but only in
univariate analysis [33].
Results from the present study indicate a diﬀerent role
of membranous β-catenin expression in rectal and colon
carcinomas. The same seems to be the case for E-cadherin
protein expression. We observed no correlation between
protein expression of E-cadherin in rectal tumor tissue and
patient prognosis, while several studies have demonstrated
a signiﬁcant association between reduced expression of E-
cadherinandimpairedpatientprognosisinpatientsoperated
f o rc o l o na d e n o c a r c i n o m a sa sw e l la so t h e rt u m o rt y p e s
[28, 55–59]. The reason for this diﬀerence regarding the
prognostic value of E-cadherin between rectal and colon
adenocarcinomas is diﬃcult to explain, but may be the result
of diﬀerent tumor biology within these two entities.
E-cadherin is one of the key proteins in epithelial-
mesenchymal transition (EMT), a process crucial for the
metastatic process. The present study indicates that the EMT
process may be diﬀerent in rectal and colon adenocarcino-
mas within the same tumor stage.
Results from the present study strongly indicate that
rectal and colon adenocarcinomas should be separated
before analyzing the prognostic value of proteins involved in
the adhesion complexes of the cells.
5. Conclusions
The present research is one of the ﬁrst studies demonstrating
tumor biological diﬀerences with signiﬁcance on protein
level between rectal and colon adenocarcinomas, regarding
the metastatic process. These diﬀerences in tumor biology
may explain some of the diﬀerences in clinical behavior
of these two tumor types, but such diﬀerences are so
far not taken into account when planning the treatment
options. The observation that p120-catenin may be related
to decreased risk of experiencing local relapse may help
stratifying patients, together with other modalities, in risk
groups for relapse.
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